{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:54:45Z","timestamp":1791554085316,"version":"4.3.4"},"reference-count":16,"publisher":"National Institute of Public Health, Prague","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Public Health","CEJPH"],"published-print":{"date-parts":[[2026,9,30]]},"DOI":"10.21101\/cejph.a8941","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:44:31Z","timestamp":1791553471000},"page":"155-159","source":"Crossref","is-referenced-by-count":0,"title":["Adult HPV vaccination (27-45 years): who benefits, when to offer, and how to counsel"],"prefix":"10.21101","volume":"34","author":[{"given":"Marek","family":"Broul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Dlouh\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Hujov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liegertov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8699","reference":[{"issue":"50","key":"ref0","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"97","author":"World Health","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"ref1","volume-title":"Evidence to recommendations for HPV vaccination of adults, ages 27 through 45 years","author":"Centers","year":"2024"},{"issue":"32","key":"ref2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref4","volume-title":"Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction","author":"European Centre","year":"2020"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070135"},{"key":"ref6","volume-title":"Efficacy, effectiveness and safety of HPV vaccination in women with conisation: a systematic review and meta-analyses","author":"European Centre","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0312128"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"20","key":"ref9","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2021.01.074","article-title":"Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: an open-label phase 3 study","volume":"39","author":"Joura EA","year":"2021","journal-title":"Vaccine"},{"key":"ref10","volume-title":"HPV vaccination recommendations","author":"Centers","year":"2024"},{"key":"ref11","volume-title":"HPV vaccine","author":"National Health","year":"2023"},{"key":"ref13","volume-title":"Adult immunization schedule notes","author":"Centers","year":"2025"},{"key":"ref14","volume-title":"vaccine safety","author":"Centers","year":"2025"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/M24-0421","article-title":"Cost-effectiveness of extending human papillomavirus vaccination to population subgroups older than 26 years who are at higher risk for human papillomavirus infection in the United States","volume":"178","author":"Laprise JF","year":"2025","journal-title":"Ann Intern Med"},{"key":"ref16","volume-title":"Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV vaccine","author":"Centers","year":"2016"},{"issue":"48","key":"ref17","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland SM","year":"2015","journal-title":"Vaccine"}],"container-title":["Central European Journal of Public Health"],"original-title":[],"link":[{"URL":"http:\/\/cejph.szu.cz\/doi\/10.21101\/cejph.a8941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:44:33Z","timestamp":1791553473000},"score":1,"resource":{"primary":{"URL":"http:\/\/cejph.szu.cz\/doi\/10.21101\/cejph.a8941.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.21101\/cejph.a8941","relation":{},"ISSN":["1210-7778","1803-1048"],"issn-type":[{"value":"1210-7778","type":"print"},{"value":"1803-1048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}